Login to Your Account

J.P. Morgan Healthcare Conference

Now Eylea Not Down Asleep: Regeneron Up for 'Dogfight'

By Randy Osborne
Staff Writer

Wednesday, January 9, 2013

As Wall Street mulled fourth-quarter sales numbers for Regeneron Pharmaceuticals Inc.'s macular degeneration drug Eylea (aflibercept), which beat expectations but disappointed some investors, CEO Leonard Schleifer spoke to the J.P. Morgan Healthcare Conference, outlining the future of the drug as it faces competition on two fronts.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription